Patents Represented by Attorney Rosemarie R. Wilk-Orescar

Find this attorney in the Justia Lawyer Directory

  • Combination therapy using an 11?-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
    Patent number: 7501405
    Abstract: Combination therapy comprising the administration of an 11?-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: March 10, 2009
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Gita Camilla Tejlgaard Kampen, Henrik Sune Andersen
  • Combination therapy using a dual PPAR-?/PPAR-? activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders
    Patent number: 7202213
    Abstract: The present invention relates to a pharmaceutical composition comprising a dual Peroxisome Proliferator-Activated Receptor-alpha/Peroxisome Proliferator-Activated Receptor-gama activator (PPAR-?/PPAR-?) and a Glucagon Like Peptide-1 (GLP-1) derivative for treating, preventing and reducing the risk of developing Type 2 diabetes, insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: April 10, 2007
    Assignee: Novo Nordisk A/S
    Inventors: John Patrick Mogensen, Per Sauerberg, Paul Stanley Bury, Lone Jeppesen, Ingrid Pettersson
  • Substituted imidazoles, their preparation and use
    Patent number: 6908926
    Abstract: Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula I wherein R1, R2, R3, R4, R5, R6, A, X, Y and Z are as defined in the specification.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: June 21, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Knud Erik Andersen, Tine Krogh Jørgensen, Bernd Peschke, Birgitte Schjellerup Wulff, Ingrid Pettersson, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Müller, Bernd Krist